Skip to main content
. Author manuscript; available in PMC: 2017 Nov 7.
Published in final edited form as: Expert Opin Investig Drugs. 2016 May 17;25(8):937–956. doi: 10.1080/13543784.2016.1182497

Figure 1. Schematic overview of current targeted therapies in HGGs.

Figure 1

Aberrant oncogenic RTK pathways including the PI3K-AKT (green) and RAS (pink) oncogenic pathways are targeted with a variety of small molecule inhibitors (grey boxes) and monoclonal antibodies. Oncometabolites produced by IDH1/2-mutated glioma cells can be intracellularly targeted by small molecule inhibitors and a IDH1 mutant specific vaccine, which is currently being tested HGG patients. Epigenetic modifiers targeting on HDAC and histone 3.3/3.1 are shown as well. Notably, various immunotherapeutic strategies that are currently undergoing evaluations in clinical trials are pictured including tumor vaccines, immune checkpoint inhibitors, CAR-T cell therapies, and oncolytic viruses (yellow box). Abbreviations: mut: mutant.